DOI:

The latest news from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)

William Wijns*, President EAPCI

As a reader of EuroIntervention Journal, percutaneous cardiovascular intervention must be your primary interest. If so, please take a few moments to read the following update news from your association, the European Association for Percutaneous Cardiovascular Interventions, known as the EAPCI.

EAPCI was formally launched at the World Congress 2006 in Barcelona as a registered branch of the European Society of cardiology. We share the ESC mission, albeit focused on our field of activity:

“To reduce the burden of cardiovascular disease in Europe

through Percutaneous Cardiovascular Interventions”

and the KEYWORDS that govern our action are:

Synergy

Focus

and Credibility.

Even though so recently born, EAPCI is already able to offer you important assets, represented by the heritage of its proud parents (EuroPCR and Working Group 10):

– EuroPCR Course, to take place this year for the first time in Barcelona, on the 22nd-25th May 2007,

– EuroPCRonline.com, featuring outstanding educational content, and the EAPCI website accessible on ESCardio.org,

– Euro Heart Survey and Registry,

– A comprehensive Education-Training-Accreditation programme,

– and not to forget, EuroIntervention Journal itself.

For EAPCI, strengths and opportunities are many. The coalition formed by the EuroPCR team – representing nearly two decades of commitment to education and teaching – along with the European Society of Cardiology – “the” representative cardiovascular medical scientific society in Europe and beyond – is a unique model. The blend of both cultures will materialise strong synergies as we consolidate our current assets and explore new activities.

At a moment where our field is experiencing another wave of expansion, leadership will be needed more than ever. To this end, EAPCI will rely entirely on a close collaboration with the national Working Groups, Societies or other bodies representing interventional communities throughout Europe, as the building blocks of our action. EAPCI can only be successful when governed by a “bottom up” relationship with its constituency.

At the beginning of the three-year term of this Board, many new initiatives are being considered, but at this present time please consider what we already have up and running right now. EAPCI leadership is structured in 8 Committees, each having a well defined mission that will be further delineated on our website and future newsletters: Communication, Euro Heart Survey, Scientific Initiatives, National Membership, Education, Fellowship, Accreditation and Clinical Initiatives. Through your national representatives, you will be asked to join and engage in these various committees, making EAPCI an essential component of your professional life in the years to come.

EAPCI Board 2006-2009.

Rows from left to right and from bottom to top,

– Marc van Sambeek, Keren Deront (EAPCI Office at ESC), Carlo Di Mario (President-Elect),

– Antoine Lafont, Sigmund Silber, Darius Dudek (Secretary),

– Martyn Thomas, Andreas Baumbach, Jean Marco, Jan-Erik Nordrehaug,

– Alberto Cremonesi, Franz Eberli, Horst Sievert (Treasurer), Franz Weidinger, William Wijns (President),

– Bernard Chevalier, Ran Kornowski, Jean Fajadet, Alec Vahanian, Alan Howard (CEO ESC).

Missing on the picture are Sally Vincent (EuroPCR office), Marc Doncieux (CEO Europa) and Patrick Serruys.

Volume 2 Number 4
Feb 20, 2007
Volume 2 Number 4
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-25-00029 Aug 4, 2025
Coronary sinus Reducer for the treatment of refractory angina: how much more evidence do we need?
Al-Lamee R and Foley M
free

Expert Review

10.4244/EIJ-D-24-00812 Aug 4, 2025
Management of device embolisation during left atrial appendage closure
Kefer J et al
free

Research Correspondence

10.4244/EIJ-D-24-01123 Aug 4, 2025
Coronary sinus narrowing for the treatment of refractory angina: one-year results of the REDUCER-I study
Verheye S et al

Editorial

10.4244/EIJ-E-25-00030 Aug 4, 2025
Expanding the boundaries of M-TEER: is it time to treat moderate secondary mitral regurgitation?
Adamo M and Riccardi M
free

Editorial

10.4244/EIJ-E-25-00035 Aug 4, 2025
The promise and pitfalls of registries for transcatheter tricuspid valve intervention
Hahn R
free

Original Research

10.4244/EIJ-D-24-01174 Aug 4, 2025
Transcatheter valve repair of tricuspid regurgitation: 1-year outcomes from the TriCLASP study
Baldus S et al
Trending articles
224.5

State-of-the-Art Review

10.4244/EIJ-D-21-00426 Dec 3, 2021
Myocardial infarction with non-obstructive coronary artery disease
Lindahl B et al
free
172.9

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
95.7

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
63

Image – Interventional flashlight

10.4244/EIJ-D-22-00074 Jun 3, 2022
Transcatheter aortic valve repair for aortic regurgitation with the Cusper device
Feld Y et al
free
58.2

Clinical research

10.4244/EIJ-D-23-00344 Sep 18, 2023
Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
Sanchez-Luna JP et al
free
49.6

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
49.6

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
31.1

Expert Review

10.4244/EIJ-D-24-00535 May 5, 2025
Catheter-based techniques for pulmonary embolism treatment
Costa F et al
30.4

Clinical Research

10.4244/EIJ-D-21-00363 Jan 28, 2022
Membranous septum morphology and risk of conduction abnormalities after transcatheter aortic valve implantation
Jørgensen T et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved